Fast Market Research

Prolor Biotech, Inc. - Product Pipeline Review - 2013 - New Study Released

Fast Market Research recommends "Prolor Biotech, Inc. - Product Pipeline Review - 2013" from Global Markets Direct, now available

 

Boston, MA -- (SBWIRE) -- 07/01/2013 -- Global Market Direct's pharmaceuticals report, "Prolor Biotech, Inc. - Product Pipeline Review - 2013" provides data on the Prolor Biotech, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Prolor Biotech, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Prolor Biotech, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.

View Full Report Details and Table of Contents

Scope

- Prolor Biotech, Inc. - Brief Prolor Biotech, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Prolor Biotech, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Prolor Biotech, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Prolor Biotech, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to Get This Report

- Evaluate Prolor Biotech, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Prolor Biotech, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Prolor Biotech, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Prolor Biotech, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Prolor Biotech, Inc. and identify potential opportunities in those areas.

Companies Mentioned in this Report: Prolor Biotech, Inc.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Prolor Biotech, Inc. - Product Pipeline Review - 2012
- Aduro BioTech, Inc. - Product Pipeline Review - 2013
- Oncolytics Biotech Inc. - Product Pipeline Review - 2013
- Active Biotech AB - Product Pipeline Review - 2013
- Generex Biotechnology Corporation - Product Pipeline Review - 2013
- Growth Hormone Deficiency - Pipeline Review, H1 2013
- Prolor Biotech, Inc. (PBTH) - Financial and Strategic SWOT Analysis Review
- Fibrosis - Pipeline Review, H1 2013
- Malignant Mesothelioma - Pipeline Review, H1 2013
- Hemophilia B - Pipeline Review, H1 2013